InvestmentMay 19, 2026, 04:07 PM
Annovis Bio Announces Proposed Public Offering of Stock and Warrants
AI Summary
Annovis Bio, Inc. announced a proposed underwritten public offering of its common stock and accompanying warrants. The shares and warrants will be offered together, with Canaccord Genuity serving as the sole bookrunner. The company intends to use the net proceeds to fund the continued Phase 3 clinical development of its lead compound, buntanetap, for Alzheimer's disease, as well as for working capital and general corporate purposes.
Key Highlights
- Annovis Bio proposes an underwritten public offering of common stock and accompanying warrants.
- Shares of common stock and warrants will be issued separately but purchased together.
- Canaccord Genuity is acting as the sole bookrunner for the offering.
- Net proceeds will fund continued Phase 3 clinical development of buntanetap for Alzheimer's disease.
- Proceeds will also be used for working capital and general corporate purposes.
- The offering is subject to market and other conditions.
Price Impact
More from ANVS